COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,046 Articles (22,627 medRxiv, 8,419 bioRxiv)

Most recent first Previous |  Page 1638: Articles 16371-16380  | Next

Assessing the impact of multiple comorbidities on fatal outcome in young COVID-19
Monroy Castillero, P., Friedman, E., Revuelta Herrera, A., Yochelis, A.
10.1101/2021.03.29.21254599 — Posted: 2021-03-31
Upregulated miR-200c may increase the risk of obese individuals to severe COVID-19
Bellae Papannarao, J., Schwenke, D., Manning, P. J., Katare, R.
10.1101/2021.03.29.21254517 — Posted: 2021-03-31
Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses.
Chandran, A., Rosenheim, J., Nageswaran, G., Swaddling, L., Pollara, G., Gupta, R., Guerra-Assuncao, J. A., Woolston, A., Ronel, T., Pade, C., Gibbons, J., Sanz-Magallon Duque De Estrada, B., Robert de Massy, M., Whelan, M., Semper, A., Brooks, T., Altmann, D. M., Boyton, R. J., McKnight, A., Manisty, C., Treibel, T. A., Moon, J., Tomlinson, G. S., Maini, M. K., Chain, B. M., Noursadeghi, M., COVIDsortium investigators
10.1101/2021.03.30.21254540 — Posted: 2021-03-31 Discussion: Onsite
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection
Marchi, S., Simonetta, V., Remarque, E., Ruello, A., Bombardieri, E., Bollati, V., Milani, G., Manenti, A., Lapini, G., Rebuffat, A., Montomoli, E., Trombetta, C.
10.1101/2021.03.29.21254534 — Posted: 2021-03-31
Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial.
Beltran Gonzalez, J. L., Gonzalez Gamez, M., Mendoza Enciso, E. A., Esparza Maldonado, R. J., Hernandez Palacios, D., Duenas Campos, S., Ovalle Robles, I., Macias Guzman, M. J., Garcia Diaz, A. L., Gutierrez Pena, C. M., Reza Escalera, A. L., Tiscareno Gutierrez, M. T., Galvan Guerra, E., Dorantes Morales, M. d. R., Martinez Medina, L., Monroy Colin, V. A., Arreola Guerra, J. M.
10.1101/2021.03.28.21254507 — Posted: 2021-03-31
A new Reproduction Index Ri and its Usefulness for Germany's Covid19-Data
Conradt, R. N. J.
10.1101/2021.03.29.21254581 — Posted: 2021-03-31
Migration of households from New York City and the Second Peak in Covid-19 cases in New Jersey, Connecticut and New York Counties.
Schulman, A. T., Bhanot, G.
10.1101/2021.03.29.21254583 — Posted: 2021-03-31
Nonpharmaceutical Interventions Remain Essential to Reducing COVID-19 Burden Even in a Well-Vaccinated Society: A Modeling Study
Leon, T. M., Vargo, J., Pan, E. S., Jain, S., Shete, P. B.
10.1101/2021.03.29.21254568 — Posted: 2021-03-31
Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
Bariola, J. R., McCreary, E. K., Wadas, R. J., Kip, K. E., Marroquin, O. C., Minnier, T., Koscumb, S., Collins, K., Schmidhofer, M., Shovel, J. A., Wisniewski, M. K., Sullivan, C., Yealy, D. M., Nace, D. A., Huang, D. T., Haidar, G., Khadem, T., Linstrum, K., Seymour, C. W., Montgomery, S. K., Angus, D. C., Snyder, G. M.
10.1101/2021.03.25.21254322 — Posted: 2021-03-30
A RANDOMIZED TRIAL - INTENSIVE TREATMENT BASED IN IVERMECTIN AND IOTA-CARRAGEENAN AS PRE-EXPOSURE PROPHYLAXIS FOR COVID- 19 IN HEALTHCARE AGENTS
Chahla, R. E., Medina Ruiz, L., Ortega, E. S., Morales, M. F., Barreiro, F., George, A., Mansilla, C., D'Amato, S. P., Barrenechea, G., Goroso, G. D., Peral de Bruno, M. d. l. A.
10.1101/2021.03.26.21254398 — Posted: 2021-03-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).